BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
manufacturing processes for high value metabolites, recombinant proteins
and enzymes, contract research and custom manufacturing for bio-products
and pharmaceutical intermediates, quality/regulatory testing and release all
raw materials, packaging materials, and final products, provision of
manufacturing operations support across operating units and product lines,
technology transfer and scale-up activities
PRODUCTS ON MARKET: Pharmaceutical bulk products:
ANALGESIC/NSAIDS: Acetaminophen, Bucetin, Oxaprozin
ANTI-ANXIETY AGENTS: Alprazolam, Fluoxetine
ANTIHYPERGLYCEMICS: Glipizide, Glibenclamide, Moclobemide
LAXATIVE: Calcium Polycarbophil
ANTIFUNGAL: Fluconazolel
ANTIHISTAMINE: Dexbrompheniramine Maleate
ANTISEPTIC: Benzalkonium Chloride 50%
CARDIOVASCULAR: Nifedipine
EXPECTORANT: Guaifenesin
ANTILIPEMIC AGENT: Pravastatin Sodium
MUSCULOSKELETAL RELAXANTS: Methocarbamol, Carisoprodol
EXCIPIENT: Sodium Starch Glycolate
IMMUNOSUPPERSSIVE AGENTS: Mycophenolate Mofetil, Rapamycin
Codexis Inc.
200 Penobscot Drive
Redwood City CA 94063, US
Phone: (650) 980-5600; Fax: (650) 298-5449
Web: www.codexis.com; E-mail: tassos.gianakakos@codexis.com
KEY PERSONNEL: Tom Baruch; Chairman
Alan Shaw, Ph.D.; President and CEO
Robert S. Breuil; Sr. VP, Finance and CFO
John Grate, Ph.D.; Sr. VP, R&D and CTO
Tassos Gianakakos; Sr. VP and Head, BU Pharmaceuticals
David Walshaw; VP, Operations
Peter Seufer-Wasserthal, Ph.D.; VP and GM, Codexis Enzymes &
Intermediates
Gregory Rocklin; VP and Head, BU Generics
EMPLOYEES: 80 employees
HISTORY: Started as the chemicals business unit of Maxygen (since 1997)
Founded in February 2002
Private spin-out from Maxygen (2004)
Acquired Julich Fine Chemicals GmbH (2/05)
Acquired assets and IP from Enzis BV (4/06)
Member--Biotechnology Industry Organization
STOCK-FINANCIAL HISTORY: Privately held
PRIVATE PLACEMENTS: Raised $25M in private financing (10/02)
Raised $37M in Series D financing (8/06)
SUBSIDIARIES/DIVISIONS: Julich Chiral Solutions GmbH--independent, wholly-owned subsidiary
SUBSIDIARY OF: Maxygen Inc. (see separate entry)
PRINCIPAL INVESTORS: Bio*One Capital Pte Ltd.
ChevronTexaco Technology Ventures
CMEA Ventures
Maxygen Inc.
Pequot Ventures
BUSINESS STRATEGY: Develop innovative bio-based solutions for pharmaceutical chemical process
development and manufacturing
Copyright ©2006 AHC Media ® 117